No Data
Alterity Therapeutics Announced That The Last Patient In The ATH434-201 Phase 2 Trial, A Randomized, Double-blind, Placebo-controlled Investigation In Early-stage Multiple System Atrophy, Has Completed The Study And Topline Results Are Expected To Be...
12 Health Care Stocks Moving In Friday's Pre-Market Session
Alterity Therapeutics Alerts Investors on Potential Risks
Alterity Therapeutics Advances in Neurodegenerative Drug Trials
Alterity Therapeutics Appoints New Company Secretary
Alterity Therapeutics Unveils New Advances for MSA Tracking
No Data
No Data
Completed.
